Torrent Pharmaceuticals shares were trading lower at ₹4,842.60 on Friday, marking a 2.91% decline from its previous close at 9:18 am during today's trading session. The stock, a constituent of the Nifty Next 50 index, experienced this downward movement as part of its ongoing market movements. According to reports from Moneycontrol, the stock is a constituent of the Nifty Next 50 index, indicating its significant market presence. The current decline is part of the stock's ongoing market movements, with investor sentiment currently assessed as very bullish by Moneycontrol analysis.
For the quarter-ending March 2026, Torrent Pharmaceuticals reported consolidated revenue of ₹4,197 crore, representing a substantial increase of 41.84% compared to ₹2,959 crore in the quarter-ending March 2025. However, the net profit for the quarter-ending March 2026 stood at ₹364 crore, representing a decline of 26.91% from ₹498 crore recorded in the same quarter of the previous year. The Earnings Per Share (EPS) for the quarter-ending March 2026 was ₹11.51, down from ₹14.71 in the corresponding quarter of the previous year, indicating a decrease of about 21.75%. The company's quarterly performance shows mixed results with strong revenue growth but profitability challenges.
The company's annual revenue has exhibited consistent growth, climbing to ₹13,979.73 crore in March 2026 from ₹8,508.04 crore in March 2022, representing a significant increase of 64.32% over this four-year period. According to Moneycontrol reports, net profit saw a steady rise, reaching ₹2,138.18 crore in March 2026 from ₹777.18 crore in March 2022, marking an impressive growth of 175.12%. The Earnings Per Share (EPS) for the year-ending March 2026 was ₹63.92, up from ₹45.93 in March 2022, indicating a growth of approximately 39.17%. The Book Value Per Share (BVPS) also showed consistent growth, increasing from ₹351.75 in March 2022 to ₹247.84 in March 2026. The Return on Equity (ROE) improved from 13.05% in 2022 to 25.78% in 2026, demonstrating enhanced capital efficiency.
The company's P/E ratio for the year-ending March 2026 stood at 66.02x, an increase from 57.16x in the previous year (March 2025). The P/B ratio also rose to 17.03x in March 2026 from 14.42x in March 2025. The Gross Profit Margin for the year-ending March 2026 was 31.93%, a slight decrease from 32.51% in March 2025. The Net Profit Margin for the year-ending March 2026 was 15.29%, showing a decline from 16.59% in March 2025. Additionally, the Debt to Equity ratio for the year-ending March 2026 was 1.76, indicating an increase in leverage compared to the ratio of 0.40 in March 2025. The company declared a dividend of ₹38.00 per share for March 2026, an increase from ₹32.00 per share in March 2025.
Torrent Pharmaceuticals has implemented several strategic corporate actions to enhance shareholder value. The company announced a final dividend of ₹9.00 per share (180%) on May 22, 2026, which became effective on May 29, 2026. This followed an interim dividend of ₹29.00 per share (580%), announced on February 4, 2026, with an effective date of February 18, 2026. The board is scheduled to meet on July 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. In 2025, the company distributed a final dividend of ₹6.00 per share (120%) and an interim dividend of ₹26.00 per share (520%). The company's cash flow from operating activities saw a strong increase, reaching ₹3,022 crore in 2026 from ₹1,802 crore in 2022, an increase of approximately 67.70%. However, cash flow from investing activities was significantly negative at ₹12,712 crore in 2026, mainly due to substantial investments.
